- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06298630
Long-term Follow-up Study of BRL-101 for TDT
March 21, 2024 updated by: Bioray Laboratories
Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Study Overview
Detailed Description
Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Study Type
Observational
Enrollment (Estimated)
45
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiaochen Wang, phD
- Phone Number: 021-64340008
- Email: xcwang@brlmed.com
Study Locations
-
-
-
Guangxi, China, 530021
- The First Affiliated Hospital of Guangxi Medical University
-
Contact:
- Yongrong Lai, PhD
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510006
- Nanfang Hospital, Southern Medical University
-
Contact:
- Xiaoqin Feng, phD
-
Guangzhou, Guangdong, China, 510006
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Contact:
- Jianpei Fang, phD
-
Shenzhen, Guangdong, China, 510006
- Shenzhen Children 's Hospital
-
Contact:
- Sixi Liu, phD
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital
-
Contact:
- Xinhua Zhang, phD
-
-
Hunan
-
Changsha, Hunan, China, 510510
- Xiangya Hospital of Central South University
-
Contact:
- Bin Fu, PhD
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- Tianjin Institute of Hematology
-
Contact:
- Jun shi, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Subjects with transfusion-dependent β-thalassemia who have been treated with BRL-101.
Description
Inclusion Criteria:
- Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
- Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Exclusion Criteria:
- There are no exclusion criteria for this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
BRL-101
All patients who have received BRL-101
|
Safety and efficacy assessments
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of hematologic malignancies
Time Frame: Up to 15 years post-drug product infusion
|
Such as new lymphoma, leukemia, MDS, etc.
|
Up to 15 years post-drug product infusion
|
Frequency, grade, and relationship of SAEs
Time Frame: Within 2 years to 5years after BRL-101 Infusion
|
Frequency, grade, and relationship to BRL-101 of SAEs following BRL-101 reinfusion.
|
Within 2 years to 5years after BRL-101 Infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Xiaochen Wang, Bioray Laboratories
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 8, 2024
Primary Completion (Estimated)
August 20, 2038
Study Completion (Estimated)
October 15, 2038
Study Registration Dates
First Submitted
March 1, 2024
First Submitted That Met QC Criteria
March 1, 2024
First Posted (Actual)
March 7, 2024
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-LTF-BRL-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thalassemia, Beta
-
M.D. Anderson Cancer CenterWithdrawnSickle Cell Disease | Sickle Beta Thalassemia | Beta Thalassemia Major | Sickle Cell-SS Disease | Sickle Beta 0 Thalassemia | Sickle Beta Plus ThalassemiaUnited States
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Editas Medicine, Inc.RecruitingHemoglobinopathies | Thalassemia Major | Thalassemia Intermedia | Transfusion Dependent Beta ThalassemiaUnited States, Canada
-
Agios Pharmaceuticals, Inc.Active, not recruitingNon-Transfusion-dependent Alpha-Thalassemia | Non-Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United Kingdom, Malaysia, United States, Netherlands, Bulgaria, Turkey, Italy, Canada, Brazil, France, United Arab Emirates, Denmark, Greece, Lebanon, Saudi Arabia
-
Ionis Pharmaceuticals, Inc.TerminatedBeta Thalassemia IntermediaAustralia, Thailand, Greece, Lebanon, Turkey
-
Lantu BiopharmaNot yet recruitingBeta-Thalassemia
-
bluebird bioCenter for International Blood and Marrow Transplant ResearchRecruitingBeta-ThalassemiaUnited States
-
Children's Hospital of Fudan UniversityCorrectSequence Therapeutics Co., LtdRecruiting
-
Assiut UniversityNot yet recruiting
Clinical Trials on Assessments
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)CompletedMood Disorders | Hypertension | Sleep | Overweight and Obesity | Vascular Stiffness | Elevated Blood PressureUnited States
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertension | Sleep | Prehypertension | Endothelial Dysfunction | Overweight and Obesity | Vascular Stiffness | Elevated Blood PressureUnited States
-
National Heart Centre SingaporeSingapore National Eye CentreUnknownMicroalbuminuria | Diastolic Dysfunction | Retinopathy, DiabeticSingapore
-
Institut National de la Santé Et de la Recherche...University College, LondonCompletedHuntington Disease | White Matter AlterationsFrance
-
Swiss Tropical & Public Health InstituteWorld BankActive, not recruitingCompliant Behavior | Morbidity;InfantSwitzerland, Congo, The Democratic Republic of the
-
University Health Network, TorontoRecruiting
-
Dokuz Eylul UniversityRecruitingRestless Legs Syndrome | Neuromyelitis OpticaTurkey
-
Memorial Sloan Kettering Cancer CenterRecruitingAcute Leukemia | Newly Diagnosed | RelapsedUnited States
-
Acibadem UniversityMarmara University; Haydarpasa Numune Training and Research HospitalRecruitingAnterior Cruciate Ligament InjuriesTurkey
-
Canan İpekUnknownNeuromuscular Diseases | Duchenne Muscular Dystrophy | Dystrophy | Dystrophy, MuscularTurkey